Three breakthrough approaches are transforming senolytic therapy beyond first-generation drugs like dasatinib-quercetin. CAR-T cells engineered to target uPAR surface markers on senescent cells demonstrate immune-based senolysis, while tissue-specific PROTACs recruit VHL E3 ligases to selectively degrade anti-apoptotic BCL-xL proteins. The third strategy leverages gut microbiome-derived butyrate to epigenetically modulate drug transporters and suppress inflammatory SASP signaling.
These precision approaches address critical limitations that have stalled clinical translation: thrombocytopenia from navitoclax, variable efficacy of broad-spectrum agents, and resistance mechanisms that allow senescent cells to evade clearance. The CAR-T strategy particularly represents a paradigm shift, applying immuno-oncology principles to aging research for the first time. However, substantial hurdles remain before clinical application, including manufacturing complexity for personalized CAR-T therapies, potential immunopathology from sustained immune activation, and unknown long-term consequences of selective senescent cell elimination. While promising, these next-generation senotherapeutics require extensive safety validation given that cellular senescence also serves protective functions in wound healing and tumor suppression.
